시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
위암 치료제 시장(2025-2032년) : 유형별, 치료 유형별, 약제 유형별, 투여 경로별, 최종 사용자별, 지역별 규모, 점유율 및 성장 분석과 산업 예측
Gastric Cancer Drugs Market Size, Share, and Growth Analysis, By Type (Adenocarcinoma, Lymphoma), By Treatment Type (Chemotherapy, Targeted Therapy), By Drug Type, By Route of Administration, By End-Users, By Region - Industry Forecast 2025-2032
상품코드 : 1764770
리서치사 : SkyQuest
발행일 : 2025년 07월
페이지 정보 : 영문 195 Pages
 라이선스 & 가격 (부가세 별도)
US $ 5,300 ￦ 7,893,000
PDF & Excel (Single User License) help
PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,200 ￦ 9,233,000
PDF & Excel (Multiple User License) help
PDF 및 Excel 보고서를 동일 사업장에서 2-5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,100 ￦ 10,574,000
PDF & Excel (Enterprise License) help
PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

위암 치료제 세계 시장 규모는 2023년 54억 달러로 평가되었고, 2024년 60억 2,000만 달러에서 2032년에는 143억 8,000만 달러로 성장할 전망이며 예측기간(2025-2032년)의 CAGR은 11.5%로 예상됩니다.

세계의 위암 치료제 시장은 이환율의 상승과 의약품 개발의 현저한 진보에 견인되어 역동적인 성장을 이룰 것으로 예측됩니다. 위암 환자의 비율 증가는 효과적인 치료법에 대한 수요를 높이고 있습니다. 기술 개발 및 투자와 지원 정책 환경에 힘입어 제약 회사, 바이오 회사, 학술 기관의 전략적 제휴가 차세대 치료의 도입을 촉진하고 있습니다. 그러나 시장 개척은 높은 개발 비용, 엄격한 규제, 저소득 지역에서의 접근 제한 등의 과제에 직면하고 있습니다. 하지만 다양한 의약품 파이프라인은 멀티 타겟 치료나 맞춤형 치료의 가능성과 함께 전도 유망한 미래를 제시하고 있습니다.

목차

소개

조사 방법

주요 요약

시장 역학과 전망

주요 시장 인사이트

위암 치료제 시장 규모 : 유형별 &CAGR(2025-2032년)

위암 치료제 시장 규모 : 치료 유형별 &CAGR(2025-2032년)

위암 치료제 시장 규모 : 약제 유형별&CAGR(2025-2032년)

위암 치료제 시장 규모 : 투여 경로별 &CAGR(2025-2032년)

위암 치료제 시장 규모 : 최종 사용자별 &CAGR(2025-2032년)

위암 치료제 시장 규모 : 지역별 &CAGR(2025-2032년)

경쟁 정보

주요 기업 프로파일

결론과 권고

CSM
영문 목차

영문목차

Global Gastric Cancer Drugs Market size was valued at USD 5.4 billion in 2023 and is poised to grow from USD 6.02 billion in 2024 to USD 14.38 billion by 2032, growing at a CAGR of 11.5% during the forecast period (2025-2032).

The global gastric cancer drugs market is poised for dynamic growth, driven by rising incidence rates and significant advancements in drug development. Increased prevalence of risk factors like obesity, smoking, and Helicobacter pylori infections is escalating the demand for effective therapies. Innovations such as targeted therapies and immunotherapies are revolutionizing treatment modalities and improving patient outcomes. Boosted by higher healthcare spending, robust R&D investments, and supportive regulatory environments, strategic partnerships among drug companies, biopharmaceutical firms, and academic institutions are facilitating the introduction of next-generation treatments. However, market growth faces challenges, including high development costs, stringent regulations, and limited access in low-income regions. Nonetheless, a diverse drug pipeline, coupled with potential multi-targeted and personalized therapies, indicates a promising future ahead.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gastric Cancer Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Gastric Cancer Drugs Market Segments Analysis

Global Gastric Cancer Drugs Market is segmented by Type, Treatment Type, Drug Type, Route of Administration, End-Users and region. Based on Type, the market is segmented into Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Others. Based on Treatment Type, the market is segmented into Chemotherapy, Targeted Therapy, Immunotherapy, Surgery, Radiation Therapy, Medication and Others. Based on Drug Type, the market is segmented into Doxorubicin Hydrochloride, Sunitinib, Mitomycin, Imatinib, Fluorouracil, Trastuzumab and Others. Based on Route of Administration, the market is segmented into Oral and Injectable. Based on End-Users, the market is segmented into Hospitals, Homecare, Specialty Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Gastric Cancer Drugs Market

The Global Gastric Cancer Drugs market is experiencing significant growth driven by the rapid development and approval of targeted therapies and immunotherapies. Advanced treatment options, including HER2 inhibitors and PD-1/PD-L1 checkpoint inhibitors, offer enhanced efficacy and improved safety compared to traditional chemotherapy. By effectively targeting specific genetic mutations and immune checkpoints, these innovations have unlocked new therapeutic possibilities, leading to better outcomes and increased survival rates for many gastric cancer patients. As pivotal clinical trials validate the effectiveness of these novel treatments, regulatory bodies and healthcare professionals are swiftly integrating them into practice, further propelling market expansion.

Restraints in the Global Gastric Cancer Drugs Market

The Global Gastric Cancer Drugs market faces substantial challenges primarily due to the prohibitive costs associated with new targeted therapies and immunotherapies. These innovative treatments often come with premium price tags, a consequence of significant research and development expenses, intricate manufacturing processes, and the need for companion diagnostics. As a result, access to these advanced therapies is largely determined by financial capability, making it difficult for patients in low- and middle-income countries to obtain them. Even in high-income nations, reimbursement obstacles and budget constraints further hinder widespread adoption, restricting patient access and slowing overall market growth.

Market Trends of the Global Gastric Cancer Drugs Market

The global gastric cancer drugs market is experiencing a significant transformation, driven by rapid advancements in artificial intelligence (AI) and data analytics. AI technologies are enhancing drug development processes, allowing for more personalized treatment options tailored to the genetic profiles of patients. This trend not only optimizes therapeutic effectiveness but also improves patient outcomes, ultimately driving increased adoption of innovative drug formulations. Additionally, the integration of AI in clinical decision-making is enabling healthcare professionals to make more informed choices, resulting in a more strategic approach to managing gastric cancer. As a result, the market is poised for substantial growth, with ongoing investments in research and development further propelling innovation.

Table of Contents

Introduction

Research Methodology

Executive Summary

Market Dynamics & Outlook

Key Market Insights

Global Gastric Cancer Drugs Market Size by Type & CAGR (2025-2032)

Global Gastric Cancer Drugs Market Size by Treatment Type & CAGR (2025-2032)

Global Gastric Cancer Drugs Market Size by Drug Type & CAGR (2025-2032)

Global Gastric Cancer Drugs Market Size by Route of Administration & CAGR (2025-2032)

Global Gastric Cancer Drugs Market Size by End-Users & CAGR (2025-2032)

Global Gastric Cancer Drugs Market Size & CAGR (2025-2032)

Competitive Intelligence

Key Company Profiles

Conclusion & Recommendations

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기